Answers are grounded in this paper and cite their sources.
Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF V600E or V600K mutations, without increased overall toxicity. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT01597908.).
No takes yet. Share an insight, caveat, or question.
Robert et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: